Orthocell has been featured in The Market Herald, announcing the appointment of Samson Medical Technologies (SMT) as its exclusive distributor for Striate+ across Australia.
Video | Stockhead Investor Presentation – June 2021
Orthocell CEO and Managing Director Paul Anderson spoke with Oriel Morrison as part of Stockhead V-Con Biotechs.
Video | Ticker News Interview – June 2021
Orthocell CEO and Managing Director, Paul Anderson, spoke with Ticker News about the positive findings from our CelGroâ„¢ clinical study.
Video | Proactive Investors – June 2021
Orthocell CEO and Managing Director Paul Anderson discusses with Proactive positive nerve regeneration results one year on from a study testing its nerve repair candidate on quadriplegic patients.
Orthocell (ASX:OCC) demonstrates potential to return function to paralysed limbs
Orthocell has been featured in The Market Herald, following the announcement of clinical data from the CelGro nerve regeneration trial demonstrating the potential to return function to paralysed upper limbs following 12 months of treatment
Read the article HERE.
Orthocell (ASX:OCC) secures Chinese and NZ patents
Orthocell has been featured in The Market Herald, following our announcement of patents granted in China and New Zealand for CelGro.
Read the article HERE.
Video | Proactive Investors – May 2021
Orthocell CEO and Managing Director Paul Anderson speaks to Proactive following the announcement newly granted patents for its CelGroâ„¢ collagen rope in China and Hong Kong.
Orthocell (ASX:OCC) granted new patents for ACL repair treatment
Orthocell has been featured in The Market Herald, following our announcement of granted patents in China and Hong Kong for its novel CelGro collagen rope device for ACL repairs.
Orthocell (ASX:OCC) receives new U.S. patent for CelGro
Orthocell has been featured in The Market Herald, following the announcement of a newly granted U.S. divisional patent for CelGro.
Read the article HERE.
Orthocell’s stock soars following FDA 510(k) clearance of regenerative collagen medical device
BioWorld has reported on Orthocell’s rising share price, following the U.S. approval for our collagen medical device for dental guided bone and soft tissue regeneration applications.